| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
NEXT GENERATION SEQUENCING, MYELOID NEOPLASIA PANEL
MessagePhysician must be contacted for approval before Add-On testing can be submitted
Must send sample with Hematopathology Patient Information Sheet. Form is linked in the Additional Information below, in the Resources section, on our website, or by calling Client Services at 219-989-3700.
Test Code
NGSMY
CPT Codes
81455
Includes
69 gene multiplexed DNA and RNA next generation sequencing panel. Assay detects single nucleotide variations, deletions / insertions, and gene fusions.
Minimum Volume
- Whole blood - 1 mL
- Bone Marrow aspirate - 0.5 mL
Other Acceptable Specimens
None
Instructions
Must include Hematopathology Patient Information Sheet with order. Form is linked in the Additional Information below, in the Resources section, on our website, or by calling Client Services at 219-989-3700.
Transport Temperature
Room temperature
Specimen Stability
- 15-30°C up to 72 hours
- 2-8°C up to 5 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
The following conditions will result in a rejeted specimen:
- FFPE block
- Frozen specimen
- Clotted specimen
Methodology
Next Generation Sequencing
Setup Schedule
At minimum, this test will be batched once every two weeks
Report Available
Report available within 14 days of receipt at the performing laboratory.
Reference Range
No alterations identified within tested genes
Clinical Significance
Testing is indicated in patients with known myeloid malignancy (AML, MDS, MPN, MDS/MPN) or peripheral blood cytopenia for greater than 4 months where reactive causes have been reasonably excluded indicated for patients seeking further treatment for tumor.
Performed By
Alverno Laboratories
Performing Laboratory
Alverno Central Lab
NMBNG (Molecular Biology, Next Gen Sequencing)
Additional Information
Hematopathology Patient Information Sheet
Last Updated: April 17, 2024
